IDEAYA Biosciences, Inc. IDYA NASDAQ

IDEAYA Biosciences, Inc. (IDYA) reported total assets of $1.11B and total liabilities of $86.39M for fiscal year 2025, resulting in total equity of $1.02B.

The company held $639.39M in cash and short-term investments. Total debt stood at $27.91M, with net debt of $-84.91M. The Debt-to-Equity (D/E) ratio was 0.03 (conservative).

Current ratio is 11.34, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.03, current ratio of 11.34 — balance sheet is strong
• MOAT (70/100) — Total assets $1.11B and equity $1.02B support the company's competitive scale
• VALUE (70/100) — Debt-to-Equity 0.03 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 58/100 with 4/7 criteria passed.

VRNA

Verona Pharma plc

$106.91

+0.11%

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

SWTX

SpringWorks Therapeutics, Inc.

$46.99

+0.02%

DAWN

Day One Biopharmaceuticals, Inc.

$21.46

-0.14%

SNDX

Syndax Pharmaceuticals, Inc.

$24.43

+0.74%